Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (22205)	12/12/2006 12:31:06 AM
From: Bio-Newbie	Read Replies (1) \| Respond to of 52153

Peter, I got a little lost in this, but is this abstract suggesting that beta blockers such as propranolol actually contribute to the development of Alzheimer's? (Asthma issue aside) Or are they saying that mediating stress through beta blockers actually decreases the development of Alz? BN

To: Biomaven who wrote (22205)	12/12/2006 4:11:39 AM
From: sim1	Read Replies (1) \| Respond to of 52153

Peter, is this the report you are referring to? Human amyloid-B synthesis and clearance rates as measured in cerebrospinal fluid in vivo Randall J Bateman 1-3, Ling Y Munsell 4, John C Morris 1,3,5, Robert Swarm 6, Kevin E Yarasheski 4, & David M Holtzman 1-3,7 Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-B (AB) in the brain and disease-causing mutations in precursor protein or in enzymes that produce AB indicate dysregulation of production or clearance of AB. Whether dysregulation of AB synthesis or clearance causes the most common form of Alzheimer disease (sporatic > 99% of cases), however, is not known. Here, we describe a method to determine the production and clearance of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of AB in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to access underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmicodynamic effects on proposed disease causing pathways. Report... neuro.wustl.edu